Last reviewed · How we verify
NCT05028803
The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids
NA trial testing sodium phenylbutyrate in Obese Non Diabetic in 6 participants. Status unknown.
1 September 2022
Quick facts
| Lead sponsor | University of Nottingham |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 September 2021 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 March 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- sodium phenylbutyrate — full drug profile →
Conditions studied
- Obese Non Diabetic — all drugs for Obese Non Diabetic →
Sponsor
University of Nottingham
Who can join
Adults 18 to 60, male only, with Obese Non Diabetic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin sensitivity measures and muscle metabolism.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.
Wu YL, Lin ZJ, Li CC, Lin X, et al · · 2023 · cited 243× · PMID 36864020 · DOI 10.1038/s41392-023-01333-7 -
Epigenetic modifications in obesity-associated diseases.
Long Y, Mao C, Liu S, Tao Y, et al · · 2024 · cited 19× · PMID 38405061 · DOI 10.1002/mco2.496
Verify or expand the search:
- PubMed search for NCT05028803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sodium phenylbutyrate
Trials testing the same drug.
- NCT03734263 — Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency. · Phase 2 · completed
Other University of Nottingham trials
Trials by the same sponsor.
- NCT07518381 — Medication Understanding in MS · not yet recruiting
- NCT07355556 — Technology Supported Improvement, Management and Prevention of Accidental Falls in Hospitals · not yet recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting
- NCT07237997 — Protein Supplementation During Dialysis (PROSED) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05028803 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nottingham
- Last refreshed: 31 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing